Peter A. Schwartzman
Corporate Officer/Principal at RADIUS HEALTH, INC.
Profile
Peter A.
Schwartzman is currently the Vice President-Capital, Strategy & Transactions at Radius Health, Inc. He was previously a Managing Director at BlackRock Advisors LLC.
He received his undergraduate degree from Trinity College (Connecticut) in 1988 and his MBA from The Leonard N Stern School of Business in 1997.
Peter A. Schwartzman active positions
| Companies | Position | Start |
|---|---|---|
| RADIUS HEALTH, INC. | Corporate Officer/Principal | 2020-10-05 |
Former positions of Peter A. Schwartzman
| Companies | Position | End |
|---|---|---|
BlackRock Advisors LLC
 BlackRock Advisors LLC Investment ManagersFinance BlackRock Advisors LLC is a SEC-registered investment advisor and mutual fund manager headquartered in New York City. The firm was founded in 1994 and is a subsidiary of BlackRock Capital Holdings, Inc., ultimately held by BlackRock, Inc. (NYSE: BLK). BlackRock Advisors manages assets for US-registered investment companies and 529 Plans. | Analyst-Fixed Income | - |
Training of Peter A. Schwartzman
| Trinity College (Connecticut) | Undergraduate Degree |
| The Leonard N Stern School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
BlackRock Advisors LLC
BlackRock Advisors LLC Investment ManagersFinance BlackRock Advisors LLC is a SEC-registered investment advisor and mutual fund manager headquartered in New York City. The firm was founded in 1994 and is a subsidiary of BlackRock Capital Holdings, Inc., ultimately held by BlackRock, Inc. (NYSE: BLK). BlackRock Advisors manages assets for US-registered investment companies and 529 Plans. | Finance |
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Peter A. Schwartzman